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Abstract
Purpose Using large-core biopsy needles in CT-guided
percutaneous transthoracic needle biopsies (PTNB) may be
advantageous in terms of larger specimens, which facilitate
more extensive histopathological, immunohistochemical,
and molecular examination of tumor tissue. The aim of this
study was to evaluate the success rate and safety in CT-
guided PTNB using 10G large-core biopsy needles.
Methods and Materials 35 patients with intrathoracic
lesions suspected of malignancy underwent CT-guided
PTNB using dedicated large-core biopsy needles (10G
SpirotomeTM, Medinvents, Hasselt, Belgium). Location,
tumor size, number of pleural passes, number of biopsies,
histologic result, and complications (pneumothorax,
bleeding) were recorded.
Results Lesion location varied from pleural to hilar lo-
cation. Mean tumor size was 3.5 cm (range 0.7–9.2 cm).
Only one pleural passage was necessary in all patients.
Mean distance from the pleura to the lesion was 2.6 cm
(max 9.2 cm). Large-core biopsy (10G) was successful in
88.6 %. Pneumothorax was found in 40 %. Minor intra-
parenchymal bleeding was present in 14 patients. No major
complications were recorded.
Conclusion Large-core biopsy with 10G did not show
higher complication rates compared to literature. It is
technically feasible and safe. The obtained larger speci-
mens may especially be helpful for the increasing demands
of extensive molecular analysis for stratified patient care.
Keywords Image-guided biopsy  Large-core
needle  Biopsy  Computed tomography (CT) 
Interventional radiology  Lung neoplasms 
Pneumothorax
Introduction
Over recent years, the treatment of lung cancer has chan-
ged significantly, necessitating a more complex approach
to pathological diagnosis of individual lung tumor speci-
mens. In addition to the precise histopathological diagnosis
and subtyping of lung tumors—which might necessitate the
use of supportive immunohistochemistry—the detection of
possible genetic mutations, translocations, and amplifica-
tions has gained more and more importance. Molecular
analysis of driver mutations is standard care in lung cancer
in the era of personalized treatment as the presence of a
driver mutation can have prognostic and predictive value-
targeted therapy [1, 2].
Only few of these molecular alterations can be detected
by immunohistochemistry such as v-raf murine sarcoma
viral oncogene homolog B1 (BRAF) and anaplastic lym-
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immunohistochemistry but the altered protein might be
detected if an antibody is available against the altered
protein, e.g., BRAF). But more often, sophisticated mole-
cular pathological methods like chromogenic or fluorescent
in situ hybridization and sequencing have to be applied.
Both, the most common, for example epidermal growth
factor receptor (EGFR), Kirsten rat sarcoma viral oncogene
homolog (KRAS) and the less frequently occurring [e.g.,
ALK, c-ros oncogene 1 (ROS1), rearranged during trans-
fection (RET), v-erb-b2 erythroblastic leukemia viral
oncogene homolog 2 (HER2)] [3, 4] mutations are con-
sidered as yet to be mutually exclusive, which means that
in some cases subsequent tests may be needed to detect or
to exclude a given mutation. Furthermore, in clinical
studies, with new targeted drugs more and more tumor
tissue is required for central biomarker testing in order to
select which patients will benefit from the investigated
compound or regimen [5]. Since at least 200–400 malig-
nant cells in a biopsy specimen are already needed to ob-
tain a histological diagnosis [6–8], the additional
expanding panel of immunohistochemical and molecular
analysis requires more tumor tissue and this may result in
more biopsies or repeated biopsy when standard size nee-
dles are used.
CT-guided percutaneous transthoracic needle biopsy
(PTNB) is widely accepted as an accurate diagnostic
method to obtain tissue for histological diagnosis in lung
lesions [9, 10] 77–96 % and low rates of complications
requiring treatment [9, 11–18]. Compared to cytological
sampling methods such as bronchoalveolar lavage or fine
needle aspiration biopsy (FNAB), histological sampling
leads to higher diagnostic accuracy and also allows
evaluation of tumur architecture [8]. As described by
Dacic, the mean number of cells obtained by using 21G
needles is C100, while with 18G CT-guided PTNB the
number of cells is C500 [6]. The mean number of cells
obtained by using different biopsy methods is summarized
in Table 1.
The use of a large-core 10G needle in CT-guided PTNB
may therefore be advantageous as with a maximal diameter
of 3 mm its maximal calculated volume is nearly nine
times the volume of a 18G needle (maximal diameter
1 mm), with consecutively a potential ninefold increase in
the number of cells per specimen. Moreover, as the
diameter of the larger core is about three times that of the
18G core, more tissue sections can be made for immuno-
histochemical analysis, which means that one single core
biopsy might already be enough for all necessary tests
(Table 2).
Therefore, the aim of this retrospective analysis was to
evaluate the success rate and safety in CT-guided PTNB
using 10G large-core biopsy needles.
Methods and Materials
In the period of December 2011 till January 2013, a total of
35 patients (17 male, 18 female, mean age 65 ± 9.5 years)
with suspected intrathoracic malignancy underwent CT-
guided PTNB under local anesthesia using dedicated l0G
large-core biopsy needles (SpirotomeTM, Medinvents,
Hasselt, Belgium) (Fig. 1). Patients were referred to our
department either as part of the routine evaluation of a
intrathoracic mass or as part of a second opinion after
biopsies elsewhere did not provide a definitive diagnosis.
The biopsies were performed under CT-guidance
(SOMATOM Sensation 16, Siemens Healthcare, Forch-
heim, Germany) using breath-hold technique if necessary.
Biopsies with 10G were only performed by or under the
supervision of two radiologists with 9 and 6 years of ex-
perience regarding transthoracic biopsies. The need for
informed consent was waived by the local ethics committee
(METC 14-4-021).
Biopsy Protocol
All patients were referred to the radiology department in
order to obtain material for further histopathological ana-
lyses of intrapulmonary lesions. In all patients, at least one
diagnostic CT scan of the chest was performed in routine
workup. If a positron emission tomography-scan (PET-s-
can) was performed in the workup, both the diagnostic scan
and the PET-scan were used to plan the biopsy, but no
other imaging technique other than CT was used for biopsy
guidance. A helical non-contrast CT scan was performed in
all patients as part of the biopsy protocol to confirm size
and location directly before the procedure. If necessary,
iodinated contrast media was administered for better de-
lineation of vascular structures. After localization on heli-
cal CT scan, the final needle path was planned and local
anesthetics were administered along the planned route. The
10G biopsy system consists of a coaxial needle system and
the biopsy needle. Figure 1 demonstrates the size differ-
ence of the 10G needle in comparison to a standard 18G
(Biopince Full-Core Biopsy Instruments, Angiotech, PBN
Medicals, Stenlose, Denmark) biopsy needle. Once the
coaxial needle was placed close to or in the lesion, the
Table 1 Number of cells per biopsy—adapted from Pirker et al. [8]
Technique and needles Number of cells Number of biopsies
21-g needle aspiration C100 4
19-g needle aspiration C150 4
Transbronchial biopsy 21-g C300 4
CT-guided needle biopsy C500 2–3
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biopsy needle was inserted and then screwed into the le-
sion. The coaxial needle was then used as a cutting needle
in order to retrieve the specimen. In general, fluoroscopy is
not used in our Department in PTNB. Obtained tissue
samples are fixated immediately in a formaldehyde
solution.
Immediately after biopsy, the patients underwent a low-
dose helical non-contrast CT scan to assess procedure re-
lated complications. Patients were observed for 2 h after
procedure. After this period, a chest X-ray was routinely
made to check for complications. When no complications
were observed the patients were discharged. In case of a














1 72 2.3 9.1 rll 28 Prone Adenosquamous carcinoma
2 63 3.6 3.2 lll 23 Prone Adenocarcinoma
3 68 2.5 1.7 lul 31 Supine Adenocarcinoma
4 56 3.3 5.5 rll 49 Prone Adenocarcinoma
5 76 2.6 1.4 lul 30 Supine Adenosquamous carcinoma
6 69 1.3 4.4 lll 55 Prone Amyloid
7 38 5.7 3 rll 45 Prone Infection
8 65 0.9 3.1 rll 23 Prone Adenocarcinoma
9 74 3.2 1.4 rll 20 Prone Adenocarcinoma
10 67 0.8 1.2 rll 27 Prone Anthrasilicosis
11 73 1.2 5.3 rul 43 Left side Adenocarcinoma
12 69 2 3.9 rll 27 Prone Adenocarcinoma
13 66 3.1 2.8 rml 32 Supine Adenocarcinoma
14 68 7.6 5.5 rul 26 Supine Sarcomatoid carcinoma
15 57 6.1 0 Pleural 36 Prone Schwannoma
16 70 2.7 2,5 rul 53 Left side NSCLC, NOS
17 71 1.8 0 rll 44 Left side Squamous metaplasia
18 76 3.9 3.6 rul 32 Supine SCLC
19 65 0.7 2.5 rul 49 Supine Endometrial carcinomac
20 60 1.5 6.3 rul 33 Prone NSCLC
21 69 5.8 2.1 rul 32 Supine Necrosis
22 45 4.1 0.2 lll 37 Prone Squamous cell carcinoma
23 76 3.9 0 rul 28 Prone Squamous cell carcinoma
24 71 3.9 0 rll 28 Left side Squamous cell carcinoma
25 68 7.1 0 rul 28 Prone Inflammation
26 58 4.3 0 rll 40 Left side Rectal carcinomac
27 75 1.9 3.6 rul 33 Supine Chronic inflammatory changes
28 69 6.7 3.5 rul 26 Prone Adenocarcinoma
29 48 1.4 2.1 lll 45 Prone Adenoid cystic carcinoma
30 49 3.7 0.7 rll 30 Left side Adenocarcinoma
31 62 5.4 0.6 lll 20 Prone Adenocarcinoma
32 58 2.8 7.1 rul 35 Prone Adenocarcinoma
33 79 3 0 Cavityb 50 Supine Adenocarcinoma
34 53 4.3 1.9 rul 45 Supine Adenocarcinoma
35 73 6.1 2.9 rul 27 Prone Squamous cell carcinoma
Mean 65 3.5 2.6 34.6
rul right upper lobe, rml right middle lobe, rll right lower lobe, lul left upper lobe, lll left lower lobe, NSCLC non-small cell lung carcinoma,
SCLC small cell lung carcinoma, NOS not-otherwise specified
a Total procedure time: in room time
b Lesion in post pneumonectomy cavity
c Lung metastasis
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complication, the need for treatment and prolonged hos-
pital stay was discussed with the chest physician. When an
asymptomatic pneumothorax was observed, the decision to
place a chest tube or discharge the patient was made by the
chest physician.
Tumor locations, tumor size, number of pleural passes,
number of biopsies, procedure time (total in room time),
complications (pneumothorax, bleeding, and hemoptysis)
were recorded. Complications were graded as minor or
major according to the quality improvement guidelines as
stated by the ACRl [19]. Diagnostic performance was
recorded by comparing histological outcome with
definitive pathology at resection when possible or, if no
resection was performed by looking at clinical outcome.
Descriptive statistics were used.
Results
Location of the lesions varied from pleural to hilar location
with mean pleura to lesion length being 2.6 cm (range
0–9.2 ± 2.2 cm). Mean tumor size was 3.5 cm (range
0.7–9.2 ± 1.8 cm). Only one pleural passage was neces-
sary in all patients. In 6 patients (17.1 %), 2 biopsy spe-
cimens were taken during the procedure without the need
for a second pleural passage. In 1 case (2.8 %), 3 biopsies
were taken with one pleural passage. In the remaining 28
cases (80.1 %), only one biopsy was taken.
Figure 2 demonstrates an example of a CT-guided
biopsy taken with a 10G needle. Figure 3 demonstrates
biopsy specimens taken by 10G needle in comparison to
18G needle biopsy from two different patients. Mean
procedure time (in room time) was 34.6 min (range
20–55 min).
On the helical thin slice CT performed, immediately
after the biopsy needle was removed a pneumothorax was
observed in 40 % (14 of 35 patients). None of these pa-
tients required placement of a chest tube at that time. The
post-procedural chest X-ray 2 h later showed a pneu-
mothorax in 20 % (7 of 35) of patients
In 2 patients without symptoms (5.6 %) a chest tube was
placed by order of the pulmonologist because of the size of
the pneumothorax, resulting in a prolonged hospital stay of
respectively 4 and 5 days therefore registered as a major
complication.
No hemoptysis or hematothorax was seen. Minor in-
traparenchymal bleeding was present in 16 cases (45.7 %)
Fig. 2 A Example of centrally located lesion (black arrow). B Biopsy
needle inside lesion (curved black arrow). C Post-procedural image
reveals needle tract bleeding surrounded by a minor intraparenchymal
bleeding (asterisk) and small pneumothorax (small arrow), all of
which were not clinically relevant
Fig. 1 10G biopsy needle (middle) with coaxial needle system (left)
and in comparison to 18G biopsy needle (right). Notice that in the
10G system the coaxial needle also serves as cutting needle
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on the helical CT scan directly after the procedure, which
did not result in hemoptysis or further complications. No
late complications were observed. An overview of the
observed complications is given in Table 3.
The large-core biopsy resulted in definitive histological
diagnosis in 31 of 35 patients. In 4 patients, histopatho-
logical analysis was not informative with regard to the
presence of tumor (detailed information on summary
findings and histology results is given in Table 2).
Discussion
Treatment of lung cancer has moved towards individual-
ized treatment using the combined assessment of im-
munohistochemical markers, mutational analyses, and
FISH techniques in order to assess the exact histology and
to detect, for example, KRAS and EGFR mutations or
ALK translocations [6, 8, 20]. These assessments increased
the need for adequate and large tumor samples. As diverse
biopsy techniques yield different amounts of tissues, it is
not always possible to apply the complete spectrum of tests
to the available tissue, sometimes requiring repeat biopsies
[6]. In our study, immunohistochemistry analyses were
performed in 33 of 35 patients and molecular analysis was
performed in 12 cases.
Large-core (10G) biopsy needles might improve diag-
nostic accuracy since their potential ninefold increase in
tissue volume compared to traditional 18G needles allows
more extensive histological analysis leaving enough ma-
terial to perform all molecular tests. Figure 4 shows a
comparison of a histological image of core samples taken
Fig. 3 Comparison of artificial tissue specimen taken by 10G needle
(left) and 18G needle (right)
Table 3 Complication rate of 10G biopsies (n = 35)
Minor complications Major complications
Pneumothorax
On CT 14 (40 %)
On X-ray 7 (20 %)





Fig. 4 Comparison of core
samples: 10G (left) historical
workup and 18G (right)
historical workup. TTFE
staining light microscopy 910
magnification
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by 10 G and 18 G needles. To our knowledge, this is the
first report on the use of 10G biopsy needles in PTNB.
In 6 cases, a second specimen was taken during the
procedure. In 1 case, the second biopsy was taken for
microbiological analyses as is customary. In 2 cases, a
second biopsy specimen was taken after the first specimen
only showed disintegrating tissue at visual inspection. In
these 2 cases, unfortunately even the second biopsy spe-
cimen did not result in a definitive histological diagnosis.
In the remaining 3 cases, a second biopsy was taken as is
customary in our institution when using 18G needles. In
hindsight, the second biopsy was not necessary since the
first obtained specimens were of sufficient quality. There-
fore, the standard procedure was adapted to ensure only
one biopsy should be taken if on visual inspection the
specimens were deemed to be of sufficient quality. In one
case, 3 biopsies were taken because of disintegrating spe-
cimens at visual inspection which eventually only showed
necrotic tissue combined with active inflammation. In
hindsight, the targeted area for biopsy was a post-ob-
structive atelectasis which was cleared on later follow-up
scans. The more centrally located cause of the obstruction
was not targeted at biopsy. In the remaining 28 cases, only
one biopsy was needed of which one was not conclusive
regarding to the histopathological diagnosis. In our insti-
tute, a cytopathologist is generally not present during
biopsy procedures.
Of the 4 cases, in which histopathological analysis did
not reveal the presence of malignancy, 3 showed inflam-
matory changes and 1 case of necrosis with acute inflam-
matory changes. It is doubtful that an 18G biopsy needle
would have had a better result. In the follow-up of these
cases, one patient died of other causes 1 year after the
biopsy without a definitive diagnosis. The second patient
developed a skin metastasis which turned out to be a
squamous cell carcinoma of probable lung origin. The third
patient was treated with radiotherapy in the assumption of a
lung malignancy and has stable disease. The fourth patient
underwent a second biopsy with 10G which resulted in the
diagnosis of a squamous cell carcinoma. Even though 10G
resulted in a definitive diagnosis, the first biopsy yielded a
negative result. Therefore, we did not include the second
biopsy in our results.
Several reports show that the use of 18–22G needles for
a CT-guided PTNB is a safe method with a relatively low
complication rate. Choo et al. reported initial results on
18G needle biopsy with cone beam CT (CBCT) guidance
and reported a sensitivity for nodules\1 cm with 96.7 %,
specificity with 100 % and accuracy of 98 % with a
complication rate of 13 % (6.5 % pneumothorax rate,
5.6 % hemoptysis) [12]. Beslic et al. even compared 14G
biopsies with 20–22G FNABs and concluded that core
biopsies yielded a higher percentage of representative
samples than FNABs (97 vs. 80 %) [21]. Some authors
suggest higher complication rates for larger needles, but
other authors demonstrated even lower complication rates
with large-core biopsies. For example, Anderson et al.
found a pneumothorax rate of 35.1 % for FNAB and
15.9 % for 18G needle biopsies [22]. Ko et al. reported on
factors which influence the pneumothorax rate [23].
Overall pneumothorax rate was 39 %, while emphysema
and lesions along fissures were associated with higher risk
of pneumothorax. Furthermore, Nakamura et al. reported in
their patient population, patient age, presence of emphy-
sema, lesion size, needle path length, number of pleural
passages, as well as the smallest angle between the pleura
and the needle as significant factors for the development of
pneumothorax (which was 59 %) [24, 25]. The number of
pneumothorax in our series seems relatively (40 %) high
using 10G needles. However, all patients with a pneu-
mothorax were asymptomatic. This rate observed on the
CT scan performed immediately after withdrawal of the
needle was lower on chest X-ray. There is no clear con-
sensus on observation and follow-up of patients after
biopsy. In our institution, all patients undergo a low-dose
thin slice helical non-contrast CT immediately after the
biopsy needle has been removed as part of the biopsy
protocol. Any small amount of air visualized in the pleural
space was considered a pneumothorax. Since there seems
to be no consensus in the grading of pneumothorax on CT
or chest X-ray, we choose to evaluate the need for chest
tube placement on symptoms (shortness of breath, chest
pain, etc.) or estimated increase of pneumothorax rather
than estimated pneumothorax size alone. Furthermore, all
patients underwent a chest X-ray two hours after biopsy to
detect complications. A retrospective analysis of 120
consecutive patients biopsied with 18G needles in our in-
stitute showed a diagnostic accuracy of 87 % and pneu-
mothorax rate of 45 %. It is not clear from the published
reports whether all institutes followed the same regimen. In
addition, no bleeding complications were observed and
prolonged hospital stay was observed in 2 of the total 35
patients due to chest tube placement. Even though both
patients were asymptomatic, according to the quality im-
provement guidelines from the ACR [19], this must be
classified as a major complication. One of these patients
with a prolonged stay of 4 days was already planned a
surgery of a head and neck tumor which took place on day
3 of his 4-day stay.
Limitations
We are presenting our initial results on 10G PTNB of
pulmonary lesions. Therefore, there are certain limitations.
First, the number of patients is limited. A more exten-
sive evaluation has to follow, especially, in terms of
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comparing the amount of tissue in the obtained specimen
and its value for extensive histological analysis in lung
cancer.
Second, biopsies with 10G were only performed by or
under the supervision of two radiologists. If not present, the
needle choice for other biopsies was to the discretion of the
performing radiologist. This of course leaves some bias in
the patient selection.
Conclusion
Large-core biopsy of lung lesions with 10G needles is
feasible and safe with comparable complication rates as in
case of standard 18G biopsies. Therefore, we conclude that
large-core needles are a safe method in obtaining larger
tissue specimens in pulmonary lesions offering the possi-
bility to assess the complete spectrum of the continuously
growing number and needs of histopathological, immuno-
histochemical, and molecular testing in lung cancer in
order to guarantee best patient care.
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